What does tissue reconstruction — total revenues mean?

This represents the total gross sales generated by the Tissue Reconstruction business segment. It serves as a primary indicator of market demand and the segment's contribution to the company's overall top-line growth.

Integra LifeSciences (IART) Tissue Reconstruction — Total Revenues

Screener

Other segment segments

Specialty Surgery

$309.27M+1.7%

Similar metrics at other companies

AMR

AMRZAggregates and other construction materials — Total Revenues

$1.3B+6.9%

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

CMEOther Revenue — Total Revenues

$115.6M+9.2%

AMR

AMRZInterproduct revenues — Total Revenues

-$151M-3.4%

NWSOther — Total Revenues

$0—

NWETotal Revenue — Total Revenues

$497.57M+6.6%

Other financials

Income statement

See full

Revenue$418.8M+0.8%

Gross profit$219.7M+5.0%

Operating income$19.3M+104%

Net income$4.5M+101%

EPS (diluted)$0.06+101%

Balance sheet

See full

Cash & equivalents$214.4M-1.6%

Total debt$2.0B+3.2%

Total equity$1.0B+0.5%

Total assets$3.6B-2.8%

Cash flow

See full

Operating cash flow$22.8M+156%

CapEx$12.3M-38.9%

Free cash flow$10.5M+193%

Valuation

See full

Market cap$1.33B+38.0%

Enterprise value$3.08B+16.2%

P/S0.8×+0.2×

Profitability

See full

Gross margin52.5%-0.1pp

Operating margin2.6%+1.3pp

Net margin-0.4%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-0.7%—

Debt / equity1.9×+0.1×

Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed: Jul 29, 2026, 4:03 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000917520-26-000058

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Neurosurgery	$213,264	$208,992	$411,458	$399,904
Surgical Instruments	54,806	53,080	102,039	104,030
ENT Solutions	41,199	41,886	78,907	80,688
Total Specialty Surgery	309,269	303,958	592,404	584,622
Wound Reconstruction Solutions	81,305	84,747	160,952	159,526
Private Label	28,187	26,900	57,323	54,110
Total Tissue Reconstruction	109,492	111,647	218,275	213,636
Total Revenue	$418,761	$415,605	$810,679	$798,258

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's tissue reconstruction — total revenues?: Integra LifeSciences (IART) reported tissue reconstruction — total revenues of $109.49M in Q2 2026.
What does tissue reconstruction — total revenues mean?: This represents the total gross sales generated by the Tissue Reconstruction business segment. It serves as a primary indicator of market demand and the segment's contribution to the company's overall top-line growth.